IQVIA’s (NYSE:IQV) Q3 2026: beats on revenue

Clinical research company IQVIA (NYSE: IQV) reported Q3 2026 results exceeding the market’s revenue expectations, with revenue up 8% year on year to $4.43 billion. The company expects the full year’s revenue to be around $17.43 billion, close to analysts’ consensus estimates. Its non-GAAP profit of $3.34 per share was 2% above analysts’ consensus estimates.